• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 144 filed by Hyperion DeFi Inc.

    7/22/25 11:20:31 AM ET
    $HYPD
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $HYPD alert in real time by email
    Form 144 Filer Information UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Form 144

    NOTICE OF PROPOSED SALE OF SECURITIES
    PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933

    FORM 144

    144: Filer Information

    Filer CIK
    0001563422
    Filer CCC
    XXXXXXXX
    Is this a LIVE or TEST Filing? Radio button checked LIVE Radio button not checked TEST

    Submission Contact Information

    Name
    Phone
    E-Mail Address

    144: Issuer Information

    Name of Issuer
    HYPERION DEFI, INC.
    SEC File Number
    001-38365
    Address of Issuer
    23461 SOUTH POINTE DRIVE,
    SUITE 390
    LAGUNA HILLS
    CALIFORNIA
    92653
    Phone
    833-393-6684
    Name of Person for Whose Account the Securities are To Be Sold
    MATHER CHARLES E IV
    See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

    Relationship to Issuer
    Director

    144: Securities Information

    Title of the Class of Securities To Be SoldName and Address of the BrokerNumber of Shares or Other Units To Be SoldAggregate Market ValueNumber of Shares or Other Units OutstandingApproximate Date of SaleName the Securities Exchange
    Common
    Fidelity Brokerage Services LLC
    245 Summer Street
    Boston � MA � 02110
    136217515.00288280807/22/2025
    NASDAQ


    Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

    144: Securities To Be Sold

    Title of the ClassDate you AcquiredNature of Acquisition TransactionName of Person from Whom AcquiredIs this a Gift?Date Donor AcquiredAmount of Securities AcquiredDate of PaymentNature of Payment *
    Common09/18/2018Open Mkt PurchasePublic MarketCheckbox not checked1209/18/2018Open market
    Common09/19/2018Open Mkt PurchasePublic MarketCheckbox not checked3709/19/2018Public Market
    Common05/28/2021Open Mkt PurchasePublic MarketCheckbox not checked3705/28/2021Open market
    Common11/01/2021Open Mkt PurchasePublic MarketCheckbox not checked4911/01/2021Open Market
    Common03/31/2022Open Mkt PurchasePublic MarketCheckbox not checked4903/31/2022Open Market
    Common05/18/2022Open Mkt PurchasePublic MarektCheckbox not checked8705/18/2022Open Market
    Common05/15/2023Open Mkt PurchasePublic MarketCheckbox not checked4905/15/2023Open Market
    Common05/26/2023Open Mkt PurchasePublic MarketCheckbox not checked3705/26/2023Open market
    Common06/17/2025Stock AwardIssuerCheckbox not checked100006/17/2025Compensation

    * If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



    Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

    144: Securities Sold During The Past 3 Months

    Nothing to ReportCheckbox checked

    144: Remarks and Signature

    Remarks
    Date of Notice
    07/22/2025

    ATTENTION:

    The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
    Signature
    /s/ Heather Foxworth as a duly authorized representative of Fidelity Brokerage Services LLC, as attorney-in-fact for MATHER CHARLES E IV

    ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

    Get the next $HYPD alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $HYPD

    DatePrice TargetRatingAnalyst
    12/24/2025Buy
    Chardan Capital Markets
    12/16/2025$4.00Overweight
    Cantor Fitzgerald
    More analyst ratings

    $HYPD
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Chardan Capital Markets initiated coverage on Hyperion Defi

    Chardan Capital Markets initiated coverage of Hyperion Defi with a rating of Buy

    12/24/25 11:52:07 AM ET
    $HYPD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cantor Fitzgerald initiated coverage on Hyperion Defi with a new price target

    Cantor Fitzgerald initiated coverage of Hyperion Defi with a rating of Overweight and set a new price target of $4.00

    12/16/25 8:52:58 AM ET
    $HYPD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $HYPD
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Financial Officer Knox David R. bought $100,340 worth of shares (27,950 units at $3.59), increasing direct ownership by 9% to 327,950 units (SEC Form 4)

    4 - HYPERION DEFI, INC. (0001682639) (Issuer)

    1/5/26 8:00:09 AM ET
    $HYPD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Strahlman Ellen R bought $113,091 worth of shares (30,880 units at $3.66), increasing direct ownership by 21% to 91,161 units (SEC Form 4)

    4 - HYPERION DEFI, INC. (0001682639) (Issuer)

    12/30/25 4:01:21 PM ET
    $HYPD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Strahlman Ellen R bought $120,664 worth of shares (38,444 units at $3.14), increasing direct ownership by 33% to 75,448 units (SEC Form 4)

    4 - HYPERION DEFI, INC. (0001682639) (Issuer)

    12/22/25 8:15:26 AM ET
    $HYPD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $HYPD
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    General Counsel Rubenstein Robert was granted 75,000 shares (SEC Form 4)

    4 - HYPERION DEFI, INC. (0001682639) (Issuer)

    1/12/26 4:02:31 PM ET
    $HYPD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 3 filed by new insider Rubenstein Robert

    3 - HYPERION DEFI, INC. (0001682639) (Issuer)

    1/12/26 4:01:12 PM ET
    $HYPD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Financial Officer Knox David R. bought $100,340 worth of shares (27,950 units at $3.59), increasing direct ownership by 9% to 327,950 units (SEC Form 4)

    4 - HYPERION DEFI, INC. (0001682639) (Issuer)

    1/5/26 8:00:09 AM ET
    $HYPD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $HYPD
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Hyperion DeFi Announces Institutional Volatility Income Vault Built on Rysk Protocol

    LAGUNA HILLS, Calif., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Hyperion DeFi, Inc. (NASDAQ:HYPD) ("Hyperion DeFi" or the "Company") today announced that it has engaged with the Rysk protocol ("Rysk") to launch a new institutional-grade, on-chain yield-enhancement vault native to the HyperEVM. Through this vault, Hyperion DeFi and its institutional partners will be able to utilize HYPE Liquid Staking Tokens (LSTs) and stablecoins as collateral for on-chain options strategies, generating additional yield beyond staking income. Hyperion DeFi will initially deploy the vault for its own balance sheet before selectively opening access to other qualified participants. Participants will be gated throug

    2/4/26 8:00:00 AM ET
    $HYPD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Hyperion DeFi Issues Letter to Shareholders

    LAGUNA HILLS, Calif., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Hyperion DeFi, Inc. (NASDAQ:HYPD) ("Hyperion DeFi" or the "Company") today issued a letter to shareholders from its Chief Executive Officer, Hyunsu Jung. To the shareholders of Hyperion DeFi, Inc.: Let me start by expressing my sincere gratitude to those sharing in our journey to become the leading Hyperliquid-native Decentralized Finance ("DeFi") company. As I formally step into the CEO role at Hyperion DeFi, I wanted to take a moment to reflect on what we've built in 2025 and what we look to accomplish in 2026. On June 17, 2025 we underwent a massive transformation from Eyenovia, a company building ophthalmic technology, to Hyper

    1/12/26 8:00:00 AM ET
    $HYPD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Hyperion DeFi Appoints Hyunsu Jung as Chief Executive Officer

    Board Confirms Leadership Team to Execute 2026 Strategic Priorities Company Also Appoints Robert Rubenstein as General Counsel LAGUNA HILLS, Calif., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Hyperion DeFi, Inc. (NASDAQ:HYPD) ("Hyperion DeFi" or the "Company") today announced that its Board of Directors has appointed Hyunsu Jung as Chief Executive Officer, effective immediately. Mr. Jung's appointment marks an important milestone in the Company's leadership evolution as it advances its strategic priorities for 2026. Mr. Jung joined Hyperion DeFi as Chief Investment Officer in June 2025, where he has focused on developing on-chain business lines, strengthening operational discipline, and expandin

    1/5/26 8:00:00 AM ET
    $HYPD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $HYPD
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Hyperion DeFi Inc.

    SCHEDULE 13G/A - HYPERION DEFI, INC. (0001682639) (Subject)

    2/5/26 6:02:20 AM ET
    $HYPD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form EFFECT filed by Hyperion DeFi Inc.

    EFFECT - HYPERION DEFI, INC. (0001682639) (Filer)

    1/12/26 12:15:16 AM ET
    $HYPD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 424B3 filed by Hyperion DeFi Inc.

    424B3 - HYPERION DEFI, INC. (0001682639) (Filer)

    1/9/26 4:30:55 PM ET
    $HYPD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $HYPD
    Leadership Updates

    Live Leadership Updates

    View All

    Hyperion DeFi Appoints Hyunsu Jung as Chief Executive Officer

    Board Confirms Leadership Team to Execute 2026 Strategic Priorities Company Also Appoints Robert Rubenstein as General Counsel LAGUNA HILLS, Calif., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Hyperion DeFi, Inc. (NASDAQ:HYPD) ("Hyperion DeFi" or the "Company") today announced that its Board of Directors has appointed Hyunsu Jung as Chief Executive Officer, effective immediately. Mr. Jung's appointment marks an important milestone in the Company's leadership evolution as it advances its strategic priorities for 2026. Mr. Jung joined Hyperion DeFi as Chief Investment Officer in June 2025, where he has focused on developing on-chain business lines, strengthening operational discipline, and expandin

    1/5/26 8:00:00 AM ET
    $HYPD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Hyperion DeFi Announces Appointment of David Knox as Chief Financial Officer

    PayPal's Former Head of Capital Markets and Head of Finance for Global Credit and Financial Services Joins Company Strong Advocate for Blockchain Adoption for Traditional Institutional Financial Products LAGUNA HILLS, Calif., Sept. 29, 2025 (GLOBE NEWSWIRE) -- Hyperion DeFi, Inc. (NASDAQ: HYPD) ("Hyperion DeFi" or the "Company"), the first U.S. publicly listed company building a long-term strategic treasury of Hyperliquid's native token, HYPE, today announced the appointment of David Knox, CFA, as Chief Financial Officer, effective immediately. This move is part of a broader strategic initiative to strengthen governance and accelerate the Company's decentralized finance ("DeFi") strateg

    9/29/25 8:00:00 AM ET
    $HYPD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $HYPD
    Financials

    Live finance-specific insights

    View All

    Hyperion DeFi Schedules Third Quarter 2025 Earnings Call for November 13, 2025

    LAGUNA HILLS, Calif., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Hyperion DeFi, Inc. (NASDAQ:HYPD) ("Hyperion DeFi" or the "Company"), the first U.S. publicly listed company dedicated to building a long-term strategic treasury of Hyperliquid's native token, HYPE, today announced that it will hold its earnings conference call and webcast for the third quarter ended September 30, 2025, on Thursday, November 13, 2025 at 5:00 p.m. Eastern Time. A press release detailing these results will be issued prior to the call on the same day. Participants may submit questions in advance of the call via email to [email protected]. A webcast of the call will be archived and available through Thursday, Novembe

    11/3/25 4:00:00 PM ET
    $HYPD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Hyperion Defi to Report Second Quarter 2025 Results on Wednesday, August 13, 2025

    NEW YORK, Aug. 08, 2025 (GLOBE NEWSWIRE) -- Hyperion Defi, Inc. (NASDAQ:HYPD), the first U.S. public company to build a strategic treasury around the HYPE token and a pioneer in integrating decentralized finance with traditional corporate treasury strategies, will host its second quarter 2025 earnings call on Wednesday, August 13, 2025, at 4:30 p.m. to review the financial and operating results. Participants should dial 1-877-407-9039 (domestic) or 1-201-689-8470 (international) with the conference code 13754799. A live webcast of the conference call will also be available here as well as on the investor relations page of the Company's corporate website at Hyperion Defi. To access the Ca

    8/8/25 4:05:00 PM ET
    $HYPD
    Biotechnology: Pharmaceutical Preparations
    Health Care